LRT Capital Management LLC Takes $2 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

LRT Capital Management LLC purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,832 shares of the medical research company's stock, valued at approximately $2,000,000. Charles River Laboratories International comprises approximately 1.6% of LRT Capital Management LLC's holdings, making the stock its 22nd biggest holding.

A number of other large investors also recently modified their holdings of the business. Fiduciary Financial Group LLC raised its holdings in shares of Charles River Laboratories International by 3.9% in the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock worth $310,000 after buying an additional 63 shares in the last quarter. Pinnacle Bancorp Inc. raised its stake in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after buying an additional 65 shares during the period. Cornerstone Investment Partners LLC raised its stake in Charles River Laboratories International by 3.7% during the 4th quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company's stock worth $358,000 after buying an additional 69 shares during the period. Metis Global Partners LLC raised its stake in shares of Charles River Laboratories International by 4.4% in the 4th quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company's stock valued at $318,000 after purchasing an additional 72 shares during the period. Finally, Two Sigma Securities LLC raised its stake in shares of Charles River Laboratories International by 4.3% in the 4th quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock valued at $366,000 after purchasing an additional 81 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CRL has been the topic of a number of recent research reports. JPMorgan Chase & Co. lowered their target price on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a research report on Thursday, February 20th. William Blair downgraded Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 22nd. Morgan Stanley lowered their target price on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. UBS Group reaffirmed a "neutral" rating and issued a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Finally, Evercore ISI upgraded Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price target for the company in a report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Charles River Laboratories International currently has an average rating of "Hold" and an average price target of $172.31.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock traded up $2.11 on Friday, hitting $141.00. 1,473,414 shares of the company traded hands, compared to its average volume of 982,522. The company has a market cap of $6.93 billion, a P/E ratio of 940.00, a P/E/G ratio of 4.54 and a beta of 1.50. The firm's 50-day simple moving average is $135.43 and its 200 day simple moving average is $164.97. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $254.15. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. The company had revenue of $984.17 million for the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm's revenue was down 2.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.27 EPS. Analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president now owns 19,513 shares in the company, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James C. Foster acquired 6,075 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the transaction, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This trade represents a 3.42% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 5,040 shares of company stock worth $807,407 in the last 90 days. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).